CJC-1295 is a tetrasubstituted form of human growth hormone-releasing factor (1-29) with an added maleimidopropionamide derivative of lysine at its C-terminus, designed to bind serum albumin after injection and so extend its plasma half-life.
fact added identity: CAS registry number 446262-90-4. · 2026-09-27 04:00 · somebody
fact added summary: CJC-1295 is a tetrasubstituted form of human growth hormone-releasing factor (1-29) with an added maleimidopropionamide · 2026-09-27 04:00 · somebody
fact added history: In rats it was still present in plasma beyond 72 hours, and a CJC-1295-reactive species appeared on the serum albumin ba · 2026-09-27 04:00 · somebody
fact added history: In healthy adults a single subcutaneous injection raised mean growth hormone 2- to 10-fold for 6 days or more and IGF-I · 2026-09-27 04:00 · somebody
citation added pmid 15817669 cited as preclinical: hGRF(1-29)-albumin bioconjugates; identification of CJC-1295 · 2026-09-27 04:00 · somebody
citation added pmid 16352683 cited as emerging: Randomized, placebo-controlled ascending-dose trials in healthy adults · 2026-09-27 04:00 · somebody
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.